)
Visual
test
Lisata Therapeutics
Lisata Therapeutics (LSTA) investor relations material
Lisata Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Mar, 2026
Executive summary
Entered into a global non-exclusive license agreement with Catalent, granting rights to develop and commercialize bioconjugate products containing certepetide and its analogs using Catalent's SMARTag® ADC platform.
Catalent will evaluate certepetide as a payload in antibody-drug conjugates (ADCs) for difficult-to-treat diseases, with the goal of creating new targeted bioconjugate therapies.
Lisata is eligible for over $10 million in tiered study initiation milestone payments and revenue sharing on future sales and partnerships.
Significant events and developments
The agreement provides Catalent with worldwide, non-exclusive rights to certepetide and its analogs for use in ADCs, including the ability to partner with third parties.
Catalent's preclinical studies demonstrated proof-of-concept for using certepetide as an ADC payload, supporting the collaboration.
The collaboration is based on positive preclinical results and is expected to be highlighted at the World ADC conference.
Capital allocation and financing
Lisata is eligible to receive over $10 million in tiered milestone payments from Catalent, plus revenue sharing on future sales and partnerships.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Lisata Therapeutics
- Q2 2024 expenses fell 19.7% as certepetide trials advance with $38.3M cash runway into 2026.LSTA
Q2 20241 Feb 2026 - Late-stage peptide therapy for solid tumors shows strong efficacy, robust funding, and key milestones ahead.LSTALD Micro Main Event XVI18 Jan 2026
- Q3 net loss narrowed, cash strong, and certepetide trials advance toward 2025 milestones.LSTAQ3 202414 Jan 2026
- Certepetide advances with strong cash, reduced loss, and key data expected in 2025.LSTAQ4 202424 Dec 2025
- Shareholders will vote on director elections, plan amendments, auditor ratification, and executive pay.LSTAProxy Filing2 Dec 2025
- Key votes include director elections, plan amendment, auditor ratification, and say-on-pay.LSTAProxy Filing2 Dec 2025
- Q1 2025 net loss narrowed, cash runway extends into Q3 2026, and clinical milestones advance.LSTAQ1 202526 Nov 2025
- Net loss narrowed, strong cash reserves, and key clinical and IP milestones drive outlook.LSTAQ2 202523 Nov 2025
- Certepetide trials advance, expenses fall, partnerships grow, and cash runway extends into 2027.LSTAQ3 202513 Nov 2025
Next Lisata Therapeutics earnings date
Q1 20267 May, 2026
Lisata Therapeutics
Next Lisata Therapeutics earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage